Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax Inc. closed 66.14% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Novavax (NVAX – Research Report) today and set a price target of ...

Novavax Inc. closed 63.58% short of its 52-week high of $23.86, which the company reached on June 6th.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day. In the most recent trading session, Novavax (NVAX) closed at $8.45 ...